Ebola Vaccines

Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.

Also Known As:

Ebolavirus Vaccine; Ebolavirus Vaccines; Vaccine, Ebola; Vaccine, Ebola Virus; Vaccine, Ebolavirus; Vaccines, Ebola; Vaccines, Ebola Virus; Vaccines, Ebolavirus; Virus Vaccine, Ebola; Virus Vaccines, Ebola; Ebola Vaccine; Ebola Virus Vaccine; Ebola Virus Vaccines

Networked: 77 relevant articles (8 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Viral Vaccines: 462
      - Ebola Vaccines: 77

Experts

1.	Feldmann, Heinz: 9 articles (12/2021 - 01/2007)
2.	Douoguih, Macaya: 5 articles (01/2022 - 04/2016)
3.	Luhn, Kerstin: 5 articles (01/2022 - 04/2016)
4.	Geisbert, Thomas W: 5 articles (02/2015 - 01/2007)
5.	Bockstal, Viki: 4 articles (01/2022 - 01/2019)
6.	Callendret, Benoit: 3 articles (01/2022 - 04/2016)
7.	Monath, Thomas P: 3 articles (01/2022 - 01/2018)
8.	Robinson, Cynthia: 3 articles (01/2022 - 01/2019)
9.	Watson-Jones, Deborah: 3 articles (01/2022 - 01/2019)
10.	Crowe, James E: 3 articles (01/2021 - 01/2019)

Related Diseases

1.	Vesicular Stomatitis 11/01/2011 - "Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy." 01/01/2007 - "Here we tested the efficacy of the vesicular stomatitis virus-based Ebola vaccine vector in post-exposure treatment in three relevant animal models. " 01/01/2020 - "The recombinant vesicular stomatitis virus (rVSV) Ebola vaccine was shown to be very efficacious in a novel ring vaccination trial in Guinea. " 01/01/2018 - "The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials." 03/15/2016 - "The live attenuated vesicular stomatitis virus-vectored Ebola vaccine rVSV-ZEBOV is currently undergoing clinical trials in West Africa. "
2.	Ebola Hemorrhagic Fever 02/01/2015 - "In addition, the development of animal models for efficacy evaluation of Ebola vaccines and the mechanism of immune protection against Ebola virus infection are also discussed. " 09/01/2014 - "While ebolavirus vaccines have been proposed as an intervention to protect apes, their effectiveness would be improved if we could diagnostically confirm Ebola virus disease (EVD) as the cause of die-offs, establish ebolavirus geographical distribution, identify immunologically naïve populations, and determine whether apes survive virus exposure. " 01/01/2017 - "Each of the three Ebola virus disease-affected countries, Sierra Leone, Guinea, and Liberia, conducted a phase II/III Ebola virus vaccine trial. " 01/01/2017 - "Declining incidence and spatial heterogeneity complicated the design of phase 3 Ebola vaccine trials during the tail of the 2013-16 Ebola virus disease (EVD) epidemic in West Africa. " 01/01/2019 - "Ebola vaccine development was accelerated in response to the 2014 Ebola virus infection outbreak. "
3.	Cystic Fibrosis (Mucoviscidosis) 01/01/2020 - "Highlights of our annual review of new approvals and launches on global drug markets include the approval and launch of Trikafta, the most widely applicable treatment to date for cystic fibrosis; approval of the first Ebola vaccine for general (rather than emergency) use; the pilot rollout in three African countries of the world's first malaria vaccine; approval of a new treatment option for multidrug-resistant bacterial infections; and the approval and launch in China of the first new drug to treat Alzheimer's disease in more than a decade. "
4.	Bacterial Infections (Bacterial Infection) 01/01/2020 - "Highlights of our annual review of new approvals and launches on global drug markets include the approval and launch of Trikafta, the most widely applicable treatment to date for cystic fibrosis; approval of the first Ebola vaccine for general (rather than emergency) use; the pilot rollout in three African countries of the world's first malaria vaccine; approval of a new treatment option for multidrug-resistant bacterial infections; and the approval and launch in China of the first new drug to treat Alzheimer's disease in more than a decade. "
5.	Alzheimer Disease (Alzheimer's Disease) 01/01/2020 - "Highlights of our annual review of new approvals and launches on global drug markets include the approval and launch of Trikafta, the most widely applicable treatment to date for cystic fibrosis; approval of the first Ebola vaccine for general (rather than emergency) use; the pilot rollout in three African countries of the world's first malaria vaccine; approval of a new treatment option for multidrug-resistant bacterial infections; and the approval and launch in China of the first new drug to treat Alzheimer's disease in more than a decade. "

Related Drugs and Biologics

1.	Vaccines
2.	Neutralizing Antibodies
3.	Malaria Vaccines
4.	tezacaftor drug combination ivacaftor elexacaftor
5.	Ebola Vaccines
6.	Antigens
7.	Glycoproteins (Glycoprotein)
8.	smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
9.	Adenovirus Vaccines
10.	Dengue Vaccines

Related Therapies and Procedures

1.	Therapeutics